Baek, J.H., Zeng, R., Weinmann-Menke, J., Valerius, M.T., Wada, Y., Ajay, A.K., Colonna, M., and Kelley, V.R. (2015). IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J. Clin. Invest. 125, 3198–3214.
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., and Zare, P. (2020). Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020 181 18, 1–19.
Baghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, N., Wira, E.P., Endo, D., Watari, H., Sakuragi, N., Hida, Y., et al. (2016). Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res. 76, 6030–6042.
Baghdadi, M., Endo, H., Tanaka, Y., Wada, H., and Seino, K. ichiro (2017). Interleukin 34, from pathogenesis to clinical applications. Cytokine 99, 139–147.
Barrett, T., Suzek, T.O., Troup, D.B., Wilhite, S.E., Ngau, W.C., Ledoux, P., Rudnev, D., Lash, A.E., Fujibuchi, W., and Edgar, R. (2005). NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res. 33.
Belkina, A.C., and Denis, G. V. (2012). BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 12, 465–477.
Berenguer-Daizé, C., Astorgues-Xerri, L., Odore, E., Cayol, M., Cvitkovic, E., Noel, K., Bekradda, M., MacKenzie, S., Rezai, K., Lokiec, F., et al. (2016). OTX015 (MK- 8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. Int. J. Cancer 139, 2047–2055.
Boulakirba, S., Pfeifer, A., Mhaidly, R., Obba, S., Goulard, M., Schmitt, T., Chaintreuil, P., Calleja, A., Furstoss, N., Orange, F., et al. (2018). IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential. Sci. Reports 2018 81 8, 1–11.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394– 424.
Cannarile, M.A., Weisser, M., Jacob, W., Jegg, A.M., Ries, C.H., and Rüttinger, D. (2017). Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 1–13.
Chaudhary, B., and Elkord, E. (2016). Regulatory T cells in the tumor microenvironment and cancer progression: Role and therapeutic targeting. Vaccines 4.
Chen, Y., Tan, W., and Wang, C. (2018). Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial–mesenchymal transition. Onco. Targets. Ther. 11, 3817–3826.
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., and Zou, Z. (2019). Tumor- associated macrophages: an accomplice in solid tumor progression. J. Biomed. Sci. 2019 261 26, 1–13.
Cioce, M., Canino, C., Goparaju, C., Yang, H., Carbone, M., and Pass, H.I. (2014). Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis. 5.
Condeelis, J., and Pollard, J.W. (2006). Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis. Cell 124, 263–266.
Cotechini, T., Medler, T.R., and Coussens, L.M. (2015). Myeloid Cells as Targets for Therapy in Solid Tumors. Cancer J. 21, 343.
Cunningham, F., Achuthan, P., Akanni, W., Allen, J., Amode, M.R., Armean, I.M., Bennett, R., Bhai, J., Billis, K., Boddu, S., et al. (2019). Ensembl 2019. Nucleic Acids Res. 47, D745–D751.
Dai, X.M., Ryan, G.R., Hapel, A.J., Dominguez, M.G., Russell, R.G., Kapp, S., Sylvestre, V., and Stanley, E.R. (2002). Targeted disruption of the mouse colony- stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111–120.
Davidov, V., Jensen, G., Mai, S., Chen, S.-H., and Pan, P.-Y. (2020). Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment. Front. Immunol. 0, 1842.
Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917.
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., et al. (2010). Selective inhibition of BET bromodomains. Nat. 2010 4687327 468, 1067–1073.
Fiskus, W., Sharma, S., Qi, J., Valenta, J.A., Schaub, L.J., Shah, B., Peth, K., Portier, B.P., Rodriguez, M., Devaraj, S.G.T., et al. (2014). Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells. Mol. Cancer Ther. 13, 1142–1154.
Fogg, D.K., Sibon, C., Miled, C., Jung, S., Aucouturier, P., Littman, D.R., Cumano, A., and Geissmann, F. (2006). A clonogenic bone harrow progenitor specific for macrophages and dendritic cells. Science (80-. ). 311, 83–87.
Foucher, E.D., Blanchard, S., Preisser, L., Garo, E., Ifrah, N., Guardiola, P., Delneste, Y., and Jeannin, P. (2013). IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM- CSF and IFNγ. PLoS One 8, e56045.
Franzè, E., Stolfi, C., Troncone, E., Scarozza, P., and Monteleone, G. (2020). Role of Interleukin-34 in Cancer. Cancers (Basel). 12.
Fu, C., Zhu, X., Xu, P., and Li, Y. (2019). Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy. Onco. Targets. Ther. 12, 609–617.
Geer, L.Y., Marchler-Bauer, A., Geer, R.C., Han, L., He, J., He, S., Liu, C., Shi, W., and Bryant, S.H. (2009). The NCBI BioSystems database. Nucleic Acids Res. 38, D492–D496.
Gilmour, J., Assi, S.A., Noailles, L., Lichtinger, M., Obier, N., and Bonifer, C. (2018). The Co-operation of RUNX1 with LDB1, CDK9 and BRD4 Drives Transcription Factor Complex Relocation During Haematopoietic Specification. Sci. Reports 2018 81 8, 1–14.
Giricz, O., Mo, Y., Dahlman, K.B., Cotto-Rios, X.M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D.B., et al. (2018). The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. JCI Insight 3.
Guillonneau, C., Bézie, S., and Anegon, I. (2017). Immunoregulatory properties of the cytokine IL-34. Cell. Mol. Life Sci. 74, 2569–2586.
Gyori, D., Lim, E.L., Grant, F.M., Spensberger, D., Roychoudhuri, R., Shuttleworth, S.J., Okkenhaug, K., Stephens, L.R., and Hawkins, P.T. (2018). Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Insight 3.
Hama, N., Kobayashi, T., Han, N., Yagita, H., Baghdadi, M., and Seino, K.-I. (2020). Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.
Han, N., Baghdadi, M., Ishikawa, K., Endo, H., Kobayashi, T., Wada, H., Imafuku, K., Hata, H., and Seino, K. (2018). Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma. Inflamm. Regen. 38.
Hashimoto, M., Niwa, O., Nitta, Y., Takeichi, M., and Yokoro, K. (1989). Unstable Expression of E-Cadherin Adhesion Molecules in Metastatic Ovarian Tumor Cells. Japanese J. Cancer Res. 80, 459–463.
De Henau, O., Rausch, M., Winkler, D., Campesato, L.F., Liu, C., Cymerman, D.H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016). Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539, 443–447.
Hunt, S.E., McLaren, W., Gil, L., Thormann, A., Schuilenburg, H., Sheppard, D., Parton, A., Armean, I.M., Trevanion, S.J., Flicek, P., et al. (2018). Ensembl variation resources. Database 2018.
Inamura, K., Shigematsu, Y., Ninomiya, H., Nakashima, Y., Kobayashi, M., Saito, H., Takahashi, K., Futaya, E., Okumura, S., Ishikawa, Y., et al. (2018). CSF1R- Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining. Cancers (Basel). 10, 252.
Jia, Y., Chng, W.J., and Zhou, J. (2019). Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. J. Hematol. Oncol. 2019 121 12, 1–17.
Jiang, Y., Li, Y., and Zhu, B. (2015). T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015 66 6, e1792–e1792.
Jones, V.S., Huang, R.Y., Chen, L.P., Chen, Z.S., Fu, L., and Huang, R.P. (2016). Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochim. Biophys. Acta - Rev. Cancer 1865, 255–265.
Jure-Kunkel, M., Masters, G., Girit, E., Dito, G., Lee, F., Hunt, J.T., and Humphrey, R. (2013). Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol. Immunother. 62, 1533– 1545.
Khan, A., and Zhang, X. (2016). dbSUPER: a database of super-enhancers in mouse and human genome. Nucleic Acids Res. 44, D164–D171.
Kumar, V., Patel, S., Tcyganov, E., and Gabrilovich, D.I. (2016). The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208.
Lei, Y., Li, X., Huang, Q., Zheng, X., and Liu, M. (2021). Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front. Oncol. 11, 609.
Li, C., Jiang, P., Wei, S., Xu, X., and Wang, J. (2020). Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer 2020 191 19, 1–23.
Lin, H., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., Halenbeck, R., Wu, G., Zhou, A., Behrens, D., et al. (2008). Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science (80-. ). 320, 807–811.
Lin, W.Y., Xu, D., Austin, C.D., Caplazi, P., Senger, K., Sun, Y., Jeet, S., Young, J., Delarosa, D., Suto, E., et al. (2019). Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer. Front. Immunol. 10, 2019.
Lovén, J., Hoke, H.A., Lin, C.Y., Lau, A., Orlando, D.A., Vakoc, C.R., Bradner, J.E., Lee, T.I., and Young, R.A. (2013). Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. Cell 153, 320–334.
Nagarajan, S., Hossan, T., Alawi, M., Najafova, Z., Indenbirken, D., Bedi, U., Taipaleenmäki, H., Ben-Batalla, I., Scheller, M., Loges, S., et al. (2014).
Bromodomain Protein BRD4 Is Required for Estrogen Receptor-Dependent Enhancer Activation and Gene Transcription. Cell Rep. 8, 460.
Neubert, N.J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018). T cell- induced CSF1 promotes melanoma resistance to PD1 blockade. Sci. Transl. Med. 10, 3311.
Niu, N., Shao, R., Yan, G., and Zou, W. (2016). Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth. J. Biol. Chem. 291, 26647–26657.
Noy, R., and Pollard, J.W. (2014). Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity 41, 49–61.
O’Donnell, J.S., Long, G. V., Scolyer, R.A., Teng, M.W.L., and Smyth, M.J. (2017). Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat. Rev. 52, 71–81.
Pan, Y., Yu, Y., Wang, X., and Zhang, T. (2020). Tumor-Associated Macrophages in Tumor Immunity. Front. Immunol. 0, 3151.
Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012 124 12, 252–264.
Pollard, J.W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004 41 4, 71–78.
Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., et al. (2015).
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N. Engl. J. Med. 372, 2006–2017.
Qian, F.C., Li, X.C., Guo, J.C., Zhao, J.M., Li, Y.Y., Tang, Z.D., Zhou, L.W., Zhang,
J., Bai, X.F., Jiang, Y., et al. (2019). SEanalysis: a web tool for super-enhancer associated regulatory analysis. Nucleic Acids Res. 47, W248–W255.
Quaranta, V., Rainer, C., Nielsen, S.R., Raymant, M.L., Ahmed, M.S., Engle, D.D., Taylor, A., Murray, T., Campbell, F., Palmer, D.H., et al. (2018). Macrophage- Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Res. 78, 4253–4269.
Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Patt, D., Chen, T.T., Berman, D.M., and Wolchok, J.D. (2015). Pooled analysis of long- term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889–1894.
Ségaliny, A.I., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., Amiaud, J., Charrier, C., Boisson-Vidal, C., and Heymann, D. (2015). Interleukin- 34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int. J. Cancer 137, 73–85.
Sengupta, D., Kannan, A., Kern, M., Moreno, M.A., Vural, E., Stack, B., Suen, J.Y., Tackett, A.J., and Gao, L. (2015). Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Epigenetics 10, 460–466.
Shao, Q., Kannan, A., Lin, Z., Stack, B.C., Suen, J.Y., and Gao, L. (2014). BET protein inhibitor JQ1 attenuates myc-amplified MCC tumor growth in vivo. Cancer Res. 74, 7090–7102.
Sharma, P., Hu-Lieskovan, S., Wargo, J.A., and Ribas, A. (2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707–723.
Sherr, C.J., Roussel, M.F., and Rettenmier, C.W. (1988). Colony‐stimulating factor‐1 receptor (c‐fms). J. Cell. Biochem. 38, 179–187.
Shoji, H., Yoshio, S., Mano, Y., Kumagai, E., Sugiyama, M., Korenaga, M., Arai, T., Itokawa, N., Atsukawa, M., Aikata, H., et al. (2016). Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci. Rep. 6.
Shultz, L.D., Lyons, B.L., Burzenski, L.M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S.D., King, M., Mangada, J., et al. (2005). Human Lymphoid and Myeloid Cell Development in NOD/LtSz- scid IL2R γ null Mice Engrafted with Mobilized Human Hemopoietic Stem Cells. J. Immunol. 174, 6477–6489.
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 71, 209–249.
Tanaka, A., and Sakaguchi, S. (2016). Regulatory T cells in cancer immunotherapy. Cell Res. 2017 271 27, 109–118.
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017). A pathology atlas of the human cancer transcriptome. Science (80-. ). 357.
Vaquerizas, J.M., Kummerfeld, S.K., Teichmann, S.A., and Luscombe, N.M. (2009). A census of human transcription factors: function, expression and evolution. Nat. Rev. Genet. 2009 104 10, 252–263.
Wang, Y., Szretter, K.J., Vermi, W., Gilfillan, S., Rossini, C., Cella, M., Barrow, A.D., Diamond, M.S., and Colonna, M. (2012). IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 13, 753–760.
Waskow, C., Liu, K., Darrasse-Jèze, G., Guermonprez, P., Ginhoux, F., Merad, M., Shengelia, T., Yao, K., and Nussenzweig, M. (2008). The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 2008 96 9, 676–683.
Wesolowski, R., Sharma, N., Reebel, L., Rodal, M.B., Peck, A., West, B.L., Marimuthu, A., Severson, P., Karlin, D.A., Dowlati, A., et al. (2019). Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther. Adv. Med. Oncol. 11.
Xiang, X., Wang, J., Lu, D., and Xu, X. (2021). Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct. Target. Ther. 2021 61 6, 1–12.
Zhou, J., Wang, G., Chen, Y., Wang, H., Hua, Y., and Cai, Z. (2019). Immunogenic cell death in cancer therapy: Present and emerging inducers. J. Cell. Mol. Med. 23, 4854–4865.
Zhou, S.-L., Hu, Z.-Q., Zhou, Z.-J., Dai, Z., Wang, Z., Cao, Y., Fan, J., Huang, X.-W., and Zhou, J. (2016). miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology 63, 1560–1575.
Zhu, Y., Yang, J., Xu, D., Gao, X.M., Zhang, Z., Hsu, J.L., Li, C.W., Lim, S.O., Sheng, Y.Y., Zhang, Y., et al. (2019). Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68, 1653–1666.
国立がん研究センターがん情報サービス「がん統計」(厚生労働省人口動態統計)